PTC Therapeutics, Inc. (PTCT) KPIs and segments
Close on Nov 13, 2026Market cap $5.30BP/E –Yield –
KPIs & segments
Operating metrics and segments that drive PTC Therapeutics's business
PTC Therapeutics's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
| Add to chart | Metric | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net product revenue($M)2 | 276 | 239 | 226 | 184 | 131 | 118 | 153 | 136 | 135 | 133 | 178 | 132 | |
United States($M) | 174 | 152 | 137 | 112 | 56.4 | 36.4 | 47.8 | 50.5 | 51.9 | 47.3 | |||
International($M) | 102 | 86.6 | 89.1 | 72.4 | 74.5 | 82.0 | 106 | 85.4 | 83.5 | 85.9 | 64.6 | ||
Sephience($M)2 | 182 | 151 | 125 | 91.6 | 19.6 | ||||||||
United States($M) | 145 | 128 | 112 | 80.7 | 14.4 | ||||||||
International($M) | 37.1 | 23.8 | 12.5 | 10.9 | 5.20 | ||||||||
Royalty revenue($M) | 81.7 | 71.1 | 46.8 | 79.4 | 70.8 | 57.6 | 36.4 | 58.2 | 61.4 | 53.2 | 31.2 | 51.0 | |
Translarna($M)1 | 48.5 | 42.2 | 59.0 | 50.7 | 59.5 | 86.2 | 72.3 | 70.4 | |||||
International($M) | 48.5 | 42.2 | 59.0 | 50.7 | 59.5 | 86.2 | 93.7 | 72.3 | 70.4 | 75.2 | |||
Emflaza($M)1 | 25.1 | 24.6 | 21.5 | 27.1 | 35.2 | 36.4 | 47.8 | 50.5 | 51.9 | 47.3 | |||
United States($M) | 25.1 | 24.6 | 21.5 | 27.1 | 35.2 | 36.4 | 47.8 | 50.5 | 51.9 | 47.3 | 67.4 | ||
Upstaza($M)2 | 15.7 | 11.9 | 1.59 | ||||||||||
International($M) | 8.84 | 11.9 | 1.59 | ||||||||||
United States($M) | 6.90 | ||||||||||||
Upstaza/Kebilidi($M)2 | 14.6 | 11.2 | 9.59 | 20.3 | 15.7 | 11.9 | 8.66 | ||||||
International($M) | 10.6 | 11.2 | 6.60 | 16.5 | 8.84 | 11.9 | 8.66 | ||||||
United States($M) | 3.96 | 0 | 3.00 | 3.88 | 6.90 | ||||||||
All other products($M)1 | 5.85 | 9.50 | 11.0 | 5.99 | 9.83 | 10.6 | 10.8 | 3.28 | 11.2 | 14.0 | |||
International($M) | 5.85 | 9.50 | 11.0 | 5.99 | 9.83 | 10.6 | 10.8 | 3.28 | 11.2 | 14.0 | |||
Collaboration and license revenue($M) | 0.23 | 50.6 | 0.14 | 9.26 | 2.94 | 986 | |||||||
Manufacturing revenue($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0.30 | 1.36 | 0.97 | ||||
Earlier reporting (last reported 2024)1 | |||||||||||||
United States($M) | 174 | 152 | 137 | 112 | 56.4 | 36.4 | 47.8 | 50.5 | 51.9 | 47.3 | |||
All other countries($M) | 67.4 | 52.8 | 44.6 | 47.7 | 40.2 | 22.9 | 57.6 | 32.0 | 53.3 | 53.4 | |||
Russia($M) | 33.0 | 8.21 | 3.25 | 18.7 | 25.1 | 41.0 | 38.5 | 49.7 | 0.97 | 2.15 | |||
Brazil($M) | 1.59 | 25.6 | 41.2 | 5.98 | 9.22 | 18.1 | 9.51 | 3.78 | 29.2 | 30.4 | |||
United States($M) | 2,525 | 1,343 | 1,583 | ||||||||||
International($M) | 374 | 362 | 313 | ||||||||||
Remaining performance obligations (RPO)($M) | 0 | 0 | 0 | ||||||||||
3 metrics have no data in the last 12 quarters — .
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
Data updated 2026-10-29.
See a number that looks wrong?